Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioMedica plc, a gene and cell therapy group, has announced that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica’s LentiVector platform technology patents.
Premaitha Health PLC, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.
In the last five years of life, total health care spending for people with dementia was more than a quarter-million…
GW Pharmaceuticals plc, has signed a Memorandum of Understanding (MOU) with the Government of New South Wales (NSW) in Australia to progress a research program for Epidiolex (cannabidiol or CBD) and cannabidivarin (CBDV) in children with severe, drug resistant childhood epilepsy.
Allergan plc and Ironwood Pharmaceuticals, Inc. have announced that Allergan has acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to Linzess (linaclotide) in Mexico from Almirall.
Strensiq is the first treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP) approved approved by FDA.
Food and Drug Administration (FDA) has approved YONDELIS (trabectedin) for the treatment of patients with unresectable (unable to be removed…
Anavex Life Sciences Corp., has announced it would be trading its common stock on the NASDAQ, an American/Canadian stock exchange, one…
The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat…
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…